Seeking Consortia & Expertise Offer for Tool-02 & Tool-03 (Bioprinting Projects)

We as Galata Innovation work with with a broad network of stakeholders in the health sector in Türkiye. One of our partner from Biomedical Engineering Department of a Health Sciences University Seeks International Consortia for Collaboration in Bioprinting Projects and offers expertise for theese calls.

University Profile: With a strong mission to be a research-oriented institution, the university’s laboratories are equipped with cutting-edge technology, particularly designed to support research in life sciences and biotechnology.

An Associate Professor from the Department of Biomedical Engineering and her team are actively seeking international consortia developing project proposals under Horizon Europe’s upcoming calls, specifically:

• HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine

• HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Potential Contributions:

Tool-02: They are developing novel bioactive hydrogel-based bio-inks for 3D bioprinting applications.

• They are specialized in bio-ink formulation and modification using both synthetic and natural polymers, with a strong background in polymer chemistry, functional polymer design and biomolecule-conjugation.

• Their expertise includes creating cell/tissue-specific bio-inks by functionalizing materials with cell-adhesive peptides.

• They have successfully conducted in vitro studies with bone and cardiac muscle cells, demonstrating robust cell attachment and proliferation on printed materials. Our work can be expanded to other cell lines, including other healthy cell lines and cancer cells, depending on project needs.

• They have a strong infrastructure for the characterization of polymeric scaffolds, like physical, chemical, morphological and mechanical properties.

• They are capable of conducting cell-specific in vitro tests, including adhesion, viability, migration, and proliferation, supporting early-stage validation of printed constructs.

• They are well-positioned to collaborate in multidisciplinary teams, especially in tasks involving bioprinting, bio-ink development, biomaterial-tissue interaction, and preclinical in vitro evaluation of bioprinted regenerative solutions.

Tool-03: They can contribute to the call specifically in the area of organoids, which are highlighted as examples of NAMs. Their lab produces hydrogel-based 3D structures that can be cellularized and used for drug screening applications.

• They utilize air-pressure-based bioprinting devices capable of printing temperature and UV-crosslinkable hydrogels, enabling precise fabrication of cell-laden constructs.

• Their experience includes working with cardiac muscle cells (heart-on-a-chip models) and bone cells, and we have the capacity to expand into brain-related cell types, including neuroblastoma, glioblastoma, and ovarian cancer cell lines.

• They are able to prepare and bioprint organoids, especially glioblastoma models, offering advanced in vitro disease platforms for drug testing and functional characterization.

• They can collaborate with companies that produce chips, providing support in hydrogel loading into chip chanel to enhance biomimetic 3D environments.

• They are capable of performing drug screening assays on bioprinted organoids by tracking cell viability,based on assays and fluorescent visualization thus contributing to precision disease modeling and personalized medicine strategies.